Format

Send to

Choose Destination
Clin J Oncol Nurs. 2006 Apr;10(2):153-4.

The role of the data safety monitoring board: why was the Avastin phase III clinical trial stopped?

Author information

1
Department of Physiologic Nursing, School of Nursing, University of California, San Francisco, USA. monica.mclemore@ucsf.edu

Abstract

In early February 2006, Genentech Inc. issued a joint press release with Roche Holding Corporation explaining that their phase III early-stage colon cancer trial of Avastin (bevacizumab, Genentech Inc., South San Francisco, CA) would be stopped after the deaths of four patients. This announcement was the result of preliminary review of the data by the Data Safety Monitoring Board (DSMB) that was formed to monitor the study. What is the DSMB? What criteria does it use to determine whether a study should be stopped early? The purpose of this article is to (a) explain the role of the DSMB, (b) give an overview of the Avastin Adjuvant (AVANT) study, and (c) provide information and resources about clinical trials for practicing RNs in oncology.

PMID:
16708697
DOI:
10.1188/06.CJON.153-154
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Oncology Nursing Society
Loading ...
Support Center